Rosuvastatin Calcium NEW

$0.00 10gkg

Min. Order5gkg
Purity99%
Cas No147098-20-2
Supply Ability1000kg
Update time2023-09-26

shan dong Fengjin Pharmaceutical company

2YR

China

Since2019-03-07

AddressNo.777 Jinnushan Road, Wuning Street, Muping District, Yantai City, Shandong Province, China

show less show more

Chemical Properties

Product Name	Rosuvastatin Calcium
CAS No	147098-20-2
EC-No
Min. Order	5gkg
Purity	99%
Supply Ability	1000kg
Release date	2023/09/26

Adjunctive therapy for patients with primary hypercholesterolaemia (type IIa, including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) when diet or exercise therapy is unsatisfactory. (Lipid-lowering). Inhibits HMG-CoA reductase and reduces the synthesis and storage of cholesterol in hepatocytes, thereby lowering total cholesterol (TC) and LDL cholesterol in the blood.

Solemn promise:

Manufacturer production and shipment, guarantee quality and effect;

National free logistics, sent to all parts of the country;

100% damage replacement, invalid full refund;

Do a good job of product quality, enhance customer benefits.

show less show more

Company Profile Introduction

　　Shandong Fengjin Pharmaceutical Co., Ltd., a wholly-owned subsidiary invested by Shandong Fengjin Biopharmaceutical Co., Ltd., is mainly engaged in the research and development, production and sales of chemical APIs, and can undertake a variety of APIs and pharmaceutical intermediates CDMO business. The company was founded in March 2019 with registered capital of RMB 66 million and plans a total investment of RMB 620 million. The project covers a total area of 200,000 square meters and is planned to be completed in three phases. The first phase covers an area of 50,000 square meters and began to construct in February 2020. The main part of the first phase has been completed. The first phase project is expected to be completed in June 2023 and put into operation in July. The company’s current phase API products include febuxostat, rosuvastatin calcium, lenvatinib mesylate, sunitinib malate, sorafenib tosylate, erlotinib hydrochloride, etc.